Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16399
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTalman, Paul-
dc.contributor.authorDuong, Thi-
dc.contributor.authorVucic, Steve-
dc.contributor.authorMathers, Susan-
dc.contributor.authorVenkatesh, Svetha-
dc.contributor.authorHenderson, Robert-
dc.contributor.authorRowe, Dominic-
dc.contributor.authorSchultz, David-
dc.contributor.authorEdis, Robert-
dc.contributor.authorNeedham, Merrilee-
dc.contributor.authorMacdonnell, Richard AL-
dc.contributor.authorMcCombe, Pamela A-
dc.contributor.authorBirks, Carol-
dc.contributor.authorKiernan, Matthew-
dc.date2016-09-30-
dc.date.accessioned2016-11-03T05:08:00Z-
dc.date.available2016-11-03T05:08:00Z-
dc.date.issued2016-09-30-
dc.identifier.citationBMJ Open 2016; 6(9): e012054en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16399-
dc.description.abstractOBJECTIVE: To capture the clinical patterns, timing of key milestones and survival of patients presenting with amyotrophic lateral sclerosis/motor neuron disease (ALS/MND) within Australia. METHODS: Data were prospectively collected and were timed to normal clinical assessments. An initial registration clinical report form (CRF) and subsequent ongoing assessment CRFs were submitted with a completion CRF at the time of death. DESIGN: Prospective observational cohort study. PARTICIPANTS: 1834 patients with a diagnosis of ALS/MND were registered and followed in ALS/MND clinics between 2005 and 2015. RESULTS: 5 major clinical phenotypes were determined and included ALS bulbar onset, ALS cervical onset and ALS lumbar onset, flail arm and leg and primary lateral sclerosis (PLS). Of the 1834 registered patients, 1677 (90%) could be allocated a clinical phenotype. ALS bulbar onset had a significantly lower length of survival when compared with all other clinical phenotypes (p<0.004). There were delays in the median time to diagnosis of up to 12 months for the ALS phenotypes, 18 months for the flail limb phenotypes and 19 months for PLS. Riluzole treatment was started in 78-85% of cases. The median delays in initiating riluzole therapy, from symptom onset, varied from 10 to 12 months in the ALS phenotypes and 15-18 months in the flail limb phenotypes. Percutaneous endoscopic gastrostomy was implemented in 8-36% of ALS phenotypes and 2-9% of the flail phenotypes. Non-invasive ventilation was started in 16-22% of ALS phenotypes and 21-29% of flail phenotypes. CONCLUSIONS: The establishment of a cohort registry for ALS/MND is able to determine clinical phenotypes, survival and monitor time to key milestones in disease progression. It is intended to expand the cohort to a more population-based registry using opt-out methodology and facilitate data linkage to other national registries.en_US
dc.subjectAmyotrophic Lateral Sclerosisen_US
dc.subjectMotor Neuron Diseaseen_US
dc.titleIdentification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohorten_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleBMJ Openen_US
dc.identifier.affiliationNeurosciences Department, University Hospital Geelong, Geelong, Victoria, Australiaen_US
dc.identifier.affiliationCenter for Pattern Recognition and Data Analytics (PRaDa), Deakin University, Waurn Ponds, Victoria, Australiaen_US
dc.identifier.affiliationSt Joseph's Hospital, Auburn, NSW, Australiaen_US
dc.identifier.affiliationCalvary Healthcare Bethlehem Hospital Neuro-Consultancy, South Caulfield, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Neurology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australiaen_US
dc.identifier.affiliationFaculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australiaen_US
dc.identifier.affiliationDepartment of Neurology, Flinders Medical Centre, Bedford Park, South Australia, Australiaen_US
dc.identifier.affiliationRoyal Perth Hospital, Shenton Park, Western Australia, Australiaen_US
dc.identifier.affiliationNeurosciences Department, Fiona Stanley Hospital, Murdoch, Western Australia, Australiaen_US
dc.identifier.affiliationNeurosciences Department, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Neurology, University of Queensland Centre for Clinical Research and Royal Brisbane and Women's Hospital, Herston, Queensland, Australiaen_US
dc.identifier.affiliationMotor Neurone Disease Association of Australia, Australiaen_US
dc.identifier.affiliationSydney Medical School, The University of Sydney, Sydney, NSW, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27694488en_US
dc.identifier.doi10.1136/bmjopen-2016-012054en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

2
checked on Mar 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.